The pathophysiology of pneumococcal pneumonia

European Respiratory Monograph

Volumn 63, Issue , 2014, Pages 42-63

  Wootton, Daniel G ^a   Aston, Stephen J ^a   Gordon, Stephen B ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; MEMBRANE PROTEIN; PILUS PROTEIN; PNEUMOCOCCAL SURFACE PROTEIN A; PNEUMOLYSIN; POLYSACCHARIDE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANTIGEN RECOGNITION; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BACTERIUM COMPETENCE; BIOFILM; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; GENETICS; HOMEOSTASIS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LOWER RESPIRATORY TRACT; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; NASOPHARYNX; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; SEPSIS; STREPTOCOCCUS PNEUMONIA; TISSUE SPECIFICITY; TRANSCRIPTOMICS; VACCINATION; VIRULENCE;

EID: 84905741655     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10003313     Document Type: Article

References (206)

1. White B, Robinson ES, Barnes LA, eds. The Biology of Pneumococcus. The Bacteriological, Biochemical, and Immunological Characters and Activities of Diplococcus pneumoniae. New York, The Commonwealth Fund, 1938.
2. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009; 374: 1543-1556.
3. Kadioglu A, Weiser JN, Paton JC, et al. The role ofStreptococcus pneumoniaevirulence factors in host respiratory colonization and disease. Nat Rev Microbiol 2008; 6: 288-301.
4. Gritzfeld JF, Wright AD, Collins AM, et al. Experimental human pneumococcal carriage. J Vis Exp 2013; 15: pi, 50115.
5. Wu HY, Virolainen A, Mathews B, et al. Establishment of aStreptococcus pneumoniaenasopharyngeal colonization model in adult mice. Microb Pathog 1997; 23: 127-137.
6. Ogunniyi AD, LeMessurier KS, Graham RMA, et al. Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity ofStreptococcus pneumoniaeD39 in a mouse model. Infect Immun 2007; 75: 1843-1851.
7. Bogaert D, de Groot R, Hermans PW. Streptococcus pneumoniaecolonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4: 144-154.
8. van Dongen TM, van der Heijden GJ, van Zon A, et al. Evaluation of concordance between the microorganisms detected in the nasopharynx and middle ear of children with otitis media. Pediatr Infect Dis J2013; 32: 549-552.
9. Rodrigues F, Foster D, Nicoli E, et al. Relationships between rhinitis symptoms, respiratory viral infections and nasopharyngeal colonization withStreptococcus pneumoniae, Haemophilus influenzaeandStaphylococcus aureusin children attending daycare. Pediatr Infect Dis J2013; 32: 227-232.
10. Simell B, Auranen K, Kayhty H, et al. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines 2012; 11: 841-855.
11. Gray BM, Converse GM, Dillon HC. Epidemiologic studies ofStreptococcus pneumoniaein infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis 1980; 142: 923-933.
12. Rapola S, Jäntti V, Haikala R, et al. Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis 2000; 182: 1146-1152.
13. Wright AKA, Bangert M, Gritzfeld JF, et al. Experimental human pneumococcal carriage augments IL-17Adependent T-cell defence of the lung. PLoS Pathog 2013; 9: 1-12.
14. Zhang Q, Leong SC, McNamara PS, et al. Characterisation of regulatory T cells in nasal associated lymphoid tissue in children: relationships with pneumococcal colonization. PLoS Pathog 2011; 7: e1002175.
15. Pido-Lopez J, Kwok WW, Mitchell TJ, et al. Acquisition of pneumococci specific effector and regulatory CD4 + T cells localising within human upper respiratory-tract mucosal lymphoid tissue. PLoS Pathog 2011; 7: e1002396.
16. Ferreira DM, Neill DR, Bangert M, et al. Controlled human infection and rechallenge withStreptococcus pneumoniaereveals the protective efficacy of carriage in healthy adults. Am J Respir Crit Care Med 2013; 187: 855-864.
17. Barocchi MA, Censini S, Rappuoli R. Vaccines in the era of genomics: the pneumococcal challenge. Vaccine 2007; 25: 2963-2973.
18. Weinberger DM, Dagan R, Givon-Lavi N, et al. Epidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriage. J Infect Dis 2008; 197: 1511-1518.
19. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused byStreptococcus pneumoniaein children younger than 5 years: global estimates. Lancet 2009; 374: 893-902.
20. Whitney CG, Pilishvili T, Jackson D, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-1746.
21. Walsh RL, Camilli A. Streptococcus pneumoniaeis desiccation tolerant and infectious upon rehydration. MBio 2011; 2: e00092-11.
22. Levine H, Balicer RD, Zarka S, et al. Dynamics of pneumococcal acquisition and carriage in young adults during training in confined settings in Israel. PLoS One 2012; 7: e46491.
23. Givon-Lavi N, Fraser D, Porat N, et al. Spread ofStreptococcus pneumoniaeand antibiotic-resistantS. pneumoniae from day-care center attendees to their younger siblings. J Infect Dis 2002; 186: 1608-1614.
24. Wright AKA, Ferreira DM, Gritzfeld JF, et al. Human nasal challenge withStreptococcus pneumoniaeis immunising in the absence of carriage. PLoS Pathog 2012; 8: e1002622.
25. Nelson AL, Roche AM, Gould JM, et al. Capsule enhances pneumococcal colonization by limiting mucusmediated clearance. Infect Immun 2007; 75: 83-90.
26. Hammerschmidt S. Adherence molecules of pathogenic pneumococci. Curr Opin Microbiol 2006; 9: 12-20.
27. Zhang JR, Mostov KE, Lamm ME, et al. The polymeric immunoglobulin receptor translocates pneumococci across human nasopharyngeal epithelial cells. Cell 2000; 102: 827-837.
28. Rose L, Shivshankar P, Hinojosa E, et al. Antibodies against PsrP, a novelStreptococcus pneumoniaeadhesin, block adhesion and protect mice against pneumococcal challenge. J Infect Dis 2008; 198: 375-383.
29. Li Y, Gierahn T, Thompson CM, et al. Distinct effects on diversifying selection by two mechanisms of immunity againstStreptococcus pneumoniae. PLoS Pathog 2012; 8: e1002989.
30. Zhang Z, Clarke TB, Weiser JN. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 2009; 119: 1899-1909.
31. Lu YJ, Gross J, Bogaert D, et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathogens 2008; 4: e1000159.
32. Mohler J, Azoulay-Dupuis E, Amory-Rivier C, et al. Streptococcus pneumoniaestrain-dependent lung inflammatory responses in a murine model of pneumococcal pneumonia. Intensive Care Med 2003; 29: 808-816.
33. Yershov AL, Jordan BS, Guymon CH, et al. Relationship between the inoculum dose ofStreptococcus pneumoniae and pneumonia onset in a rabbit model. Eur Respir J2005; 25: 693-700.
34. Cabre M. Pneumonia in the elderly. Curr Opin Pulm Med 2009; 15: 223-229.
35. Janoff EN, Breiman RF, Daley CL, et al. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 1992; 117: 314-324.
36. Glennie SJ, Banda D, Gould K, et al. Defective pneumococcal-specific Th1 responses in HIV-infected adults precedes a loss of control of pneumococcal colonization. Clin Infect Dis 2013; 56: 291-299.
37. Meyer KC. The role of immunity and inflammation in lung senescence and susceptibility to infection in the elderly. Semin Respir Crit Care Med 2010; 31: 561-574.
38. Ridda I, Macintyre CR, Lindley R, et al. Lack of pneumococcal carriage in the hospitalised elderly. Vaccine 2010; 28: 3902-3904.
39. Welte T, Kohnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin Respir Crit Care Med 2009; 30: 127-135.
40. Neill DR, Fernandes VE, Wisby L, et al. T regulatory cells control susceptibility to invasive pneumococcal pneumonia in mice. PLoS Pathog 2012; 8: e1002660.
41. Raynor J, Lages CS, Shehata H, et al. Homeostasis and function of regulatory T cells in aging. Curr Opin Immunol 2012; 24: 482-487.
42. Charlson ES, Bittinger K, Bushman FD, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011; 184: 957-963.
43. Oggioni MR, Trappetti C, Kadioglu A, et al. Switch from planktonic to sessile life: a major event in pneumococcal pathogenesis. Mol Microbiol 2006; 61: 1196-1210.
44. Arnold RR, Brewer M, Gauthier JJ. Bactericidal activity of human lactoferrin: sensitivity of a variety of microorganisms. Infect Immun 1980; 28: 893-898.
45. Dajani R, Zhang YL, Taft PJ, et al. Lysozyme secretion by submucosal glands protects the airway from bacterial infection. Am J Physiol Lung Cell Mol Biol 2005; 32: 548-552.
46. Cruse G, Fernandes VE, De Salort J, et al. Human lung mast cells mediate pneumococcal cell death in response to activation by pneumolysin. J Immunol 2010; 184: 7108-7115.
47. Masuda S, Murakami M, Mitsuishi M, et al. Expression of secretory phospholipase A2 enzymes in lungs of humans with pneumonia and their potential prostaglandin-synthetic function in human lung-derived cells. Biochem J2005; 387: 27-38.
48. Tecle T, Tripathi S, Hartshorn KL. Defensins and cathelicidins in lung immunity. Innate Immunity 2010; 16: 151-159.
49. Zhao H, Kinnunen PKJ. Modulation of the activity of secretory phospholipase A2 by antimicrobial peptides. Antimicrob Agents Chemother 2003; 47: 965.
50. Haczku A. Protective role of the lung collectins surfactant protein A and surfactant protein D in airway inflammation. J Allergy Clin Immunol 2008; 122: 861-879.
51. Jounblat R, Clark H, Eggleton P, et al. The role of surfactant protein D in the colonisation of the respiratory tract and onset of bacteraemia during pneumococcal pneumonia. Respir Res 2005; 6: 126-126.
52. Dockrell DH, Marriott HM, Prince LR, et al. Alveolar macrophage apoptosis contributes to pneumococcal clearance in a resolving model of pulmonary infection. J Immunol 2003; 171: 5380-5388.
53. Pradeu T, Cooper EL. The danger theory: 20 years later. Front Immunol 2012; 3: 287.
54. Eberl G. A new vision of immunity: homeostasis of the superorganism. Mucosal Immunol 2010; 3: 450-460.
55. Kadioglu A, Gingles NA, Grattan K, et al. Host cellular immune response to pneumococcal lung infection in mice. Infect Immun 2000; 68: 492-501.
56. Mulholland K. Perspectives on the burden of pneumonia in children. Vaccine25: 2394-2397.
57. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 2007; 7: 875-888.
58. Knapp S, Leemans JC, Florquin S, et al. Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med 2003; 167: 171-179.
59. Paterson GK, Orihuela CJ. Pneumococci: immunology of the innate host response. Respirology 2010; 15: 1057-1063.
60. Schröder NWJ, Morath S, Alexander C, et al. Lipoteichoic acid (LTA) ofStreptococcus pneumoniaeand Staphylococcus aureusactivates immune cellsviaToll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 2003; 278: 15587-15594.
61. Albiger B, Dahlberg S, Sandgren A, et al. Toll-like receptor 9 acts at an early stage in host defence against pneumococcal infection. Cell Microbiol 2007; 9: 633-644.
62. McNeela EA, Burke A, Neill DR, et al. Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. PLoS Pathog 2010; 6: e1001191.
63. Jounai N, Kobiyama K, Takeshita F, et al. Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination. Front Cell Infect Microbiol 2012; 2: 168-168.
64. Jiang DH, Liang JR, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev 2011; 91: 221-264.
65. Didierlaurent A, Goulding J, Patel S, et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 2008; 205: 323-329.
66. Eddens T, Kolls JK. Host defenses against bacterial lower respiratory tract infection. Curr Opin Immunol 2012; 24: 424-430.
67. Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 2005; 5: 58-68.
68. Clement CG, Evans SE, Evans CM, et al. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am J Respir Crit Care Med 2008; 177: 1322-1330.
69. Murdoch C, Read RC, Zhang Q, et al. Choline-binding protein A ofStreptococcus pneumoniaeelicits chemokine production and expression of intercellular adhesion molecule 1 (CD54) by human alveolar epithelial cells. J Infect Dis 2002; 186: 1253-1260.
70. Cundell DR, Gerard NP, Gerard C, et al. Streptococcus pneumoniaeanchor to activated human cells by the receptor for platelet-activating factor. Nature 1995; 377: 435-438.
71. Weiser JN, Bae D, Fasching C, et al. Antibody-enhanced pneumococcal adherence requires IgA1 protease. Proc Natl Acad Sci USA2003; 100: 4215-4220.
72. Snelgrove RJ, Goulding J, Didierlaurent AM, et al. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol 2008; 9: 1074-1083.
73. Findlay EG, Hussell T. Macrophage-mediated inflammation and disease: a focus on the lung. Mediators Inflamm 2012; 140937: 1-6.
74. Janssen WJ, McPhillips KA, Dickinson MG, et al. Surfactant proteins A and D suppress alveolar macrophage phagocytosisviainteraction with SIRP alpha. Am J Respir Crit Care Med 2008; 178: 158-167.
75. Guth AM, Janssen WJ, Bosio CM, et al. Lung environment determines unique phenotype of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2009; 296: L936-L946.
76. Hussell T, Cavanagh MM. The innate immune rheostat: influence on lung inflammatory disease and secondary bacterial pneumonia. Biochem Soc Trans 2009; 37: 811-813.
77. Davis KM, Nakamura S, Weiser JN. Nod2 sensing of lysozyme-digested peptidoglycan promotes macrophage recruitment and clearance ofS. pneumoniaecolonization in mice. J Clin Invest 2011; 121: 3666-3676.
78. Bordon J, Aliberti S, Fernandez-Botran R, et al. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protectiveversusdeleterious inflammatory response in pneumonia. Int J Infect Dis 2013; 17: e76-e83.
79. Remmelts HHF, Meijvis SCA, Kovaleva A, et al. Changes in serum cortisol levels during community-acquired pneumonia: the influence of dexamethasone. Respir Med 2012; 106: 905-908.
80. Kadioglu A, De Filippo K, Bangert M, et al. The Integrins Mac-1 anda4b1perform crucial roles in neutrophil and T cell recruitment to lungs duringStreptococcus pneumoniaeinfection. J Immunol 2011; 186: 5907-5915.
81. Klesney-Tait J, Keck K, Li X, et al. Transepithelial migration of neutrophils into the lung requires TREM-1. J Clin Invest 2013; 123: 138-149.
82. Yoshida K, Kondo R, Wang Q, et al. Neutrophil cytoskeletal rearrangements during capillary sequestration in bacterial pneumonia in rats. Am J Respir Crit Care Med 2006; 174: 689-698.
83. Cundell DR, Gerard C, Idanpaan HI, et al. PAf receptor anchorsStreptococcus pneumoniaeto activated human endothelial cells. Adv Exp Med Biol 1996; 416: 89-94.
84. Sano H, Kuronuma K, Takahashi H, et al. Pulmonary surfactant protein A augments the phagocytosis of Streptococcus pneumoniaeby alveolar macrophages through a casein kinase 2-dependent increase of cell surface localization of scavenger receptor A. Trends Glycosci Glycotechnol 2004; 16: L4-L12.
85. Dorrington MG, Chauvin SE, Tu Z, et al. MARCO is required for TLR2-and Nod2-mediated responses to Streptococcus pneumoniaeand clearance of pneumococcal colonization in the murine nasopharynx. J Immunol 2013; 190: 250-258.
86. Gould JM, Weiser JN. Expression of C-reactive protein in the human respiratory tract. Infect Immun 2001; 69: 1747-1754.
87. Tino MJ, Wright JR. Surfactant protein A stimulates phagocytosis of specific pulmonary pathogens by alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 1996; 270: L677-L688.
88. Hartshorn KL, White MR, Colamussi ML, et al. Pulmonary surfactant proteins A and D enhance neutrophil uptake of bacteria. Am J Physiol Lung Cell Mol Physiol 1998; 274: L958-L969.
89. Ivanov S, Fontaine J, Paget C, et al. Key role for respiratory CD103 + dendritic cells, IFN-c, and IL-17 in protection againstStreptococcus pneumoniaeinfection in response toa-galactosylceramide. J Infect Dis 2012; 206: 723-734.
90. Noske N, Hammerschmidt S, Kämmerer U, et al. Pneumococcal interaction with human dendritic cells: phagocytosis, survival, and induced adaptive immune response are manipulated by PavA. J Immunol 2009; 183: 1952-1963.
91. Rosendahl A, Bergmann S, Hammerschmidt S, et al. Lung dendritic cells facilitate extrapulmonary bacterial dissemination during pneumococcal pneumonia. Front Cell Infect Microbiol 2013; 3: 21.
92. Khan AQ, Lees A, Snapper CM. Differential regulation of IgG anti-capsular polysaccharide and antiprotein responses to intactStreptococcus pneumoniaein the presence of cognate CD4 + T cell help. J Immunol 2004; 172: 532-539.
93. Lipsitch M, Whitney CG, Zell E, et al. Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease?PLoS Med 2005; 2: e15.
94. Gordon SB, Irving GR, Lawson RA, et al. Intracellular trafficking and killing ofStreptococcus pneumoniaeby human alveolar macrophages are influenced by opsonins. Infect Immun 2000; 68: 2286-2293.
95. Koppel EA, Litjens M, van den Berg, et al. Interaction of SIGNR1 expressed by marginal zone macrophages with marginal zone B cells is essential to early IgM responses againstStreptococcus pneumoniae. Mol Immunol 2008; 45: 2881-2887.
96. Podolsky SH, ed. Pneumonia before Antibiotics: Therapeutic Evolution and Evaluation in Twentieth-Century America. Baltimore, Johns Hopkins University Press, 2006.
97. Aberdein J, Cole J, Bewley M, et al. Alveolar macrophages in pulmonary host defence-the unrecognised role of apoptosis as a mechanism of intracellular bacterial killing. Clin Exp Immunol 2013; 174: 193-202.
98. McCubbrey AL, Curtis JL. Efferocytosis and lung disease. Chest 2013; 143: 1750-1757.
99. Kirby AC, Newton DJ, Carding SR, et al. Pulmonary dendritic cells and alveolar macrophages are regulated by gamma delta T cells during the resolution ofS. pneumoniae-induced inflammation. J Pathol 2007; 212: 29-37.
100. Brouwer MC, de Gans J, Heckenberg SG, et al. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 31-44.
101. Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 2010; 23: 740-780.
102. Brown JS, Hussell T, Gilliland SM, et al. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniaeinfection in mice. Proc Natl Acad Sci USA2002; 99: 169-174.
103. Bousfiha A, Picard C, Boisson-Dupuis S, et al. Primary immunodeficiencies of protective immunity to primary infections. Clin Immunol, 135: 204-209.
104. Chapman SJ, Khor CC, Vannberg FO, et al. Common NFKBIL2 polymorphisms and susceptibility to pneumococcal disease: a genetic association study. Crit Care 2010; 14: R227.
105. García-Laorden MI, Rodríguez de Castro F, Solé-ViolánJ, et al. The role of mannose-binding lectin in pneumococcal infection. Eur Respir J2013; 41: 131-139.
106. Roy S, Knox K, Segal S, et al. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet 2002; 359: 1569-1573.
107. Bougle A, Max A, Mongardon N, et al. Protective effects of FCGR2A polymorphism in invasive pneumococcal diseases. Chest 2012; 142: 1474-1481.
108. Parvaneh N, Casanova JL, Notarangelo LD, et al. Primary immunodeficiencies: a rapidly evolving story. J Allergy Clin Immunol 2013; 131: 314-323.
109. McCavit TL, Xuan L, Zhang S, et al. Hospitalization for invasive pneumococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure. Pediatr Blood Cancer 2012; 58: 945-949.
110. Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. Lancet 2011; 378: 86-97.
111. Ezzati M, Kammen D. Indoor air pollution from biomass combustion and acute respiratory infections in Kenya: an exposure-response study. Lancet 2001; 358: 619-624.
112. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000; 342: 681-689.
113. Mortimer K, Gordon SB, Jindal SK, et al. Household air pollution is a major avoidable risk factor for cardiorespiratory disease. Chest 2012; 142: 1308-1315.
114. Jambo KC, Sepako E, Fullerton DG, et al. Bronchoalveolar CD4+ T cell responses to respiratory antigens are impaired in HIV-infected adults. Thorax 2011; 66: 375-382.
115. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 1995; 333: 845-851.
116. Gordon SB, Molyneux ME, Boeree MJ, et al. Opsonic phagocytosis ofStreptococcus pneumoniaeby alveolar macrophages is not impaired in human immunodeficiency virus-infected Malawian adults. J Infect Dis 2001; 184: 1345-1349.
117. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-2365.
118. Boikos C, Quach C. Risk of invasive pneumococcal disease in children and adults with asthma: a systematic review. Vaccine 2013; 31: 4820-4826.
119. Inghammar M, Engström G, Kahlmeter G, et al. Invasive pneumococcal disease in patients with an underlying pulmonary disorder. Clin Microbiol Infect2013 [In press DOI: 10. 1111/1469-0691].
120. Joos L, Tamm M. Breakdown of pulmonary host defense in the immunocompromised host: cancer chemotherapy. Proc Am Thorac Soc 2005; 2: 445-448.
121. Ek A, Larsson K, Siljerud S, et al. Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy 1999; 54: 691-699.
122. Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine 2003; 21: Suppl. 2, S24-S34.
123. O'Brien DP, Nahm MH, Briles DE, et al. Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniaeinfections. Infect Immun 1999; 67: 595-601.
124. Vogelgesang A, Grunwald U, Langner S, et al. Analysis of lymphocyte subsets in patients with stroke and their influence on infection after stroke. Stroke 2008; 39: 237-241.
125. Gordon SB, Miller DE, Day RB, et al. Pulmonary immunoglobulin responses toStreptococcus pneumoniaeare altered but not reduced in human immunodeficiency virus-infected Malawian adults. JInfectDis 2003; 188: 666-670.
126. Eagan R, Twigg HL, French N, et al. Lung fluid immunoglobulin from HIV-infected subjects has impaired opsonic function against pneumococci. Clin Infect Dis 2007; 44: 1632-1638.
127. Cilloniz C, Polverino E, Ewig S, et al. Impact of age and comorbidity on etiology and outcome in communityacquired pneumonia. Chest 2013; 144: 999-1007.
128. Rohde GGU. The role of viruses in CAP. In: Chalmers JD, Pletz MW, Aliberti S, eds. Community-Acquired Pneumonia. Eur Respir Monogr 2014; 63: 74-87.
129. McCullers JA, Rehg JE. Lethal synergism between influenza virus andStreptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor 1. J Infect Dis 2002; 186: 341-350.
130. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med 2008; 14: 558-564.
131. Hussell T, Goulding J. Structured regulation of inflammation during respiratory viral infection. Lancet Infect Dis 2010; 10: 360-366.
132. Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest 2012; 122: 2749-2755.
133. Fujimori T, Snelgrove R, Hussell T. TAM receptors and their role in the regulation of lung innate immunity. J Immunol 2013; 190: 124. 29.
134. Kaphalia L, Calhoun WJ. Alcoholic lung injury: metabolic, biochemical and immunological aspects. Toxicol Lett 2013; 222: 171-179.
135. Mehta AJ, Yeligar SM, Elon L, et al. Alcoholism causes alveolar macrophage zinc deficiency and immune dysfunction. Am J Respir Crit Care Med 2013; 188: 716-723.
136. Hyams C, Trzcinski K, Camberlein E, et al. Streptococcus pneumoniaecapsular serotype invasiveness correlates with the degree of factor H binding and opsonization with C3b/iC3b. Infect Immun 2013; 81: 354-363.
137. Hyams C, Camberlein E, Cohen JM, et al. TheStreptococcus pneumoniaecapsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect Immun 2010; 78: 704-715.
138. Wartha F, Beiter K, Albiger B, et al. Capsule and D-alanylated lipoteichoic acids protectStreptococcus pneumoniae against neutrophil extracellular traps. Cell Microbiol 2007; 9: 1162-1171.
139. Shaper M, Hollingshead SK, Benjamin WH J, et al. PspA protectsStreptococcus pneumoniaefrom killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin. Infect Immun 2004; 72: 5031-5040.
140. Tu AH, Fulgham RL, McCrory MA, et al. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun 1999; 67: 4720-4724.
141. Ren B, Li J, Genschmer K, et al. The absence of PspA or presence of antibody to PspA facilitates the complementdependent phagocytosis of pneumococciin vitro. Clin Vaccine Immunol 2012; 19: 1574-1582.
142. Quin LR, Carmicle S, Dave S, et al. In vivobinding of complement regulator factor H byStreptococcus pneumoniae. J Infect Dis 2005; 192: 1996-2003.
143. Ogunniyi AD, Grabowicz M, Mahdi LK, et al. Pneumococcal histidine triad proteins are regulated by the Zn2 +-dependent repressor AdcR and inhibit complement deposition through the recruitment of complement factor H. FASEB J2009; 23: 731-738.
144. Beiter K, Wartha F, Albiger B, et al. An endonuclease allowsStreptococcus pneumoniaeto escape from neutrophil extracellular traps. Curr Biol 2006; 16: 401-407.
145. Dalia AB, Standish AJ, Weiser JN. Three surface exoglycosidases fromStreptococcus pneumoniae, NanA, BgaA, and StrH, promote resistance to opsonophagocytic killing by human neutrophils. Infect Immun 2010; 78: 2108-2116.
146. Brittan JL, Buckeridge TJ, Finn A, et al. Pneumococcal neuraminidase A: an essential upper airway colonization factor for Streptococcus pneumoniae. Mol Oral Microbiol 2012; 27: 270-283.
147. King SJ, Hippe KR, Weiser JN. Deglycosylation of human glycoconjugates by the sequential activities of exoglycosidases expressed byStreptococcus pneumoniae. Mol Microbiol 2006; 59: 961-974.
148. Jedrzejas MJ. Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev 2001; 65: 187-207.
149. Agarwal V, Hammerschmidt S, Malm S, et al. Enolase ofStreptococcus pneumoniaebinds human complement inhibitor C4b-binding protein and contributes to complement evasion. J Immunol 2012; 189: 3575-3584.
150. Bergmann S, Rohde M, Preissner KT, et al. The nine residue plasminogen-binding motif of the pneumococcal enolase is the major cofactor of plasmin-mediated degradation of extracellular matrix, dissolution of fibrin and transmigration. Thromb Haemost 2005; 94: 304-311.
151. Lammerts Van Bueren A, Ficko-Blean E, Pluvinage B, et al. The conformation and function of a multimodular glycogen-degrading pneumococcal virulence factor. Structure 2011; 19: 640-651.
152. Nelson AL, Ries J, Bagnoli F, et al. RrgA is a pilus-associated adhesin inStreptococcus pneumoniae. Mol Microbiol 2007; 66: 329-340.
153. Orrskog S, Rounioja S, Spadafina T, et al. Pilus adhesin RrgA interacts with complement receptor 3, thereby affecting macrophage function and systemic pneumococcal disease. MBio 2012; 4: e00535-12.
154. Paterson GK, Mitchell TJ. The role ofStreptococcus pneumoniaesortase A in colonisation and pathogenesis. Microbes Infect 2006; 8: 145-153.
155. Holmes AR, McNab R, Millsap KW, et al. The pavA gene ofStreptococcus pneumoniaeencodes a fibronectinbinding protein that is essential for virulence. Mol Microbiol 2001; 41: 1395-1408.
156. Kadioglu A, Brewin H, Hartel T, et al. Pneumococcal protein PavA is important for nasopharyngeal carriage and development of sepsis. Mol Oral Microbiol 2010; 25: 50-60.
157. Jensch I, Gámez G, Petruschka L, et al. PavB is a surface-exposed adhesin ofStreptococcus pneumoniae contributing to nasopharyngeal colonization and airways infections. Mol Microbiol 2010; 77: 22-43.
158. Khan MN, Sharma SK, Filkins LM, et al. PcpA ofStreptococcus pneumoniaemediates adherence to nasopharyngeal and lung epithelial cells and elicits functional antibodies in humans. Microbes Infect 2012; 14: 1102-1110.
159. Marriott HM, Mitchell TJ, Dockrell DH. Pneumolysin: a double-edged sword during the host-pathogen interaction. Curr Mol Med 2008; 8: 497-509.
160. Knapp S, von Aulock S, Leendertse M, et al. Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor. J Immunol 2008; 180: 3478-3484.
161. Brown JS, Ogunniyi AD, Woodrow MC, et al. Immunization with components of two iron uptake ABC transporters protects mice against systemic Streptococcus pneumoniaeinfection. Infect Immun 2001; 69: 6702-6706.
162. Yesilkaya H, Kadioglu A, Gingles N, et al. Role of manganese-containing superoxide dismutase in oxidative stress and virulence ofStreptococcus pneumoniae. Infect Immun 2000; 68: 2819-2826.
163. Park CY, Kim EH, Choi SY, et al. Virulence attenuation ofStreptococcus pneumoniae clpPmutant by sensitivity to oxidative stress in macrophagesviaan NO-mediated pathway. J Microbiol 2010; 48: 229-235.
164. Dawid S, Roche AM, Weiser JN. The blp bacteriocins ofStreptococcus pneumoniaemediate intraspecies competition bothin vitro andin vivo. Infect Immun 2007; 75: 443-451.
165. Pericone CD, Overweg K, Hermans PW, et al. Inhibitory and bactericidal effects of hydrogen peroxide production byStreptococcus pneumoniaeon other inhabitants of the upper respiratory tract. Infect Immun 2000; 68: 3990-3997.
166. Blomberg C, Dagerhamn J, Dahlberg S, et al. Pattern of accessory regions and invasive disease potential in Streptococcus pneumoniae. J Infect Dis 2009; 199: 1032-1042.
167. McAllister LJ, Ogunniyi AD, Stroeher UH, et al. Contribution of serotype and genetic background to virulence of serotype 3 and serogroup 11 pneumococcal isolates. Infect Immun 2011; 79: 4839-4849.
168. Silva NA, McCluskey J, Jefferies JM, et al. Genomic diversity between strains of the same serotype and multilocus sequence type among pneumococcal clinical isolates. Infect Immun 2006; 74: 3513-3518.
169. Trappetti C, van der Maten C, Amin Z, et al. Site of isolation determines biofilm formation and virulence phenotypes ofStreptococcus pneumoniaeserotype 3 clinical isolates. Infect Immun 2013; 81: 505-513.
170. Obert C, Sublett J, Kaushal D, et al. Identification of a candidate Streptococcus pneumoniaecore genome and regions of diversity correlated with invasive pneumococcal disease. Infect Immun 2006; 74: 4766-4777.
171. Sanchez CJ, Hinojosa CA, Shivshankar P, et al. Changes in capsular serotype alter the surface exposure of pneumococcal adhesins and impact virulence. PLoS One 2011; 6: e26587.
172. Orihuela CJ, Gao G, Francis KP, et al. Tissue-specific contributions of pneumococcal virulence factors to pathogenesis. J Infect Dis 2004; 190: 1661-1669.
173. Ogunniyi AD, Mahdi LK, Trappetti C, et al. Identification of genes that contribute to the pathogenesis of invasive pneumococcal disease byin vivo transcriptomic analysis. Infect Immun 2012; 80: 3268-3278.
174. Avery OT, Dubos R. The protective action of a specific enzyme against type III pneumococcus infection in mice. J Exp Med 1931; 54: 73-89.
175. Weinberger DM, Harboe ZB, Sanders EA, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010; 51: 692-699.
176. Hirst RA, Kadioglu A, O'Callaghan C, et al. The role of pneumolysin in pneumococcal pneumonia and meningitis. Clin Exp Immunol 2004; 138: 195-201.
177. Hammerschmidt S, Wolff S, Hocke A, et al. Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells. Infect Immun 2005; 73: 4653-4667.
178. Weiser JN, Bae D, Epino H, et al. Changes in availability of oxygen accentuate differences in capsular polysaccharide expression by phenotypic variants and clinical isolates ofStreptococcus pneumoniae. Infect Immun 2001; 69: 5430-5439.
179. Malley R, Henneke P, Morse SC, et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA2003; 100: 1966-1971.
180. Dessing MC, Hirst RA, de Vos AF, et al. Role of Toll-like receptors 2 and 4 in pulmonary inflammation and injury induced by pneumolysin in mice. PLoS One 2009; 4: e7993-e7993.
181. Witzenrath M, Pache F, Lorenz D, et al. The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. J Immunol 2011; 187: 434-440.
182. Harvey RM, Ogunniyi AD, Chen AY, et al. Pneumolysin with low hemolytic activity confers an early growth advantage toStreptococcus pneumoniaein the blood. Infect Immun 2011; 79: 4122-4130.
183. Kirkham LA, Jefferies JM, Kerr AR, et al. Identification of invasive serotype 1 pneumococcal isolates that express nonhemolytic pneumolysin. J Clin Microbiol 2006; 44: 151-159.
184. Briles DE, Hollingshead SK, Paton JC, et al. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection withStreptococcus pneumoniae. J Infect Dis 2003; 188: 339-348.
185. Ogunniyi AD, Folland RL, Briles DE, et al. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge withStreptococcus pneumoniae. Infect Immun 2000; 68: 3028-3033.
186. Salha D, Szeto J, Myers L, et al. Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injury. Infect Immun 2012; 80: 2212-2220.
187. Kamtchoua T, Bologa M, Hopfer R, et al. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults. Vaccine 2013; 31: 327-333.
188. Anderson R, Steel HC, Cockeran R, et al. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin byStreptococcus pneumoniae in vitro. J Antimicrob Chemother 2007; 60: 1155-1158.
189. Briles DE, Hollingshead SK, King J, et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection withStreptococcus pneumoniae bearing heterologous PspA. J Infect Dis 2000; 182: 1694-1701.
190. Barocchi MA, Ries J, Zogaj X, et al. A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci USA2006; 103: 2857-2862.
191. LeMieux J, Hava DL, Basset A, et al. RrgA and RrgB are components of a multisubunit pilus encoded by the Streptococcus pneumoniaerlrA pathogenicity islet. Infect Immun 2006; 74: 2453-2456.
192. Basset A, Zhang F, Benes C, et al. Toll-like receptor (TLR) 2 mediates inflammatory responses to oligomerized RrgA pneumococcal pilus type 1 protein. J Biol Chem 2013; 288: 2665-2675.
193. Gianfaldoni C, Censini S, Hilleringmann M, et al. Streptococcus pneumoniaepilus subunits protect mice against lethal challenge. Infect Immun 2007; 75: 1059-1062.
194. Basset A, Trzcinski K, Hermos C, et al. Association of the pneumococcal pilus with certain capsular serotypes but not with increased virulence. J Clin Microbiol 2007; 45: 1684-1689.
195. Johnsborg O, Håvarstein LS. Regulation of natural genetic transformation and acquisition of transforming DNA in Streptococcus pneumoniae. FEMS Microbiol Rev 2009; 33: 627-642.
196. Håvarstein LS, Coomaraswamy G, Morrison DA. An unmodified heptadecapeptide pheromone induces competence for genetic transformation inStreptococcus pneumoniae. Proc Natl Acad Sci USA1995; 92: 11140-11144.
197. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348: 1747-1755.
198. Gordon SB, Jambo K, Molyneux ME, et al. Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses. Vaccine 2008; 26: 5400-5406.
199. Clutterbuck EA, Lazarus R, Bowman J, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012; 205: 1408-1416.
200. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008; 121: 219-225.
201. Nie W, Zhang Y, Cheng J, et al. Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS One 2012; 7: e47926.
202. Waterer GW. Are macrolides now obligatory in severe community-acquired pneumonia?Intensive Care Med 2010; 36: 562-564.
203. Doshi SM, Kulkarni PA, Liao JM, et al. The impact of statin and macrolide use on early survival in patients with pneumococcal pneumonia. Am J Med Sci 2013; 345: 173-177.
204. Steinwede K, Henken S, Bohling J, et al. TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice. J Exp Med 2012; 209: 1937-1952.
205. Bangert M, Bricio-Moreno L, Gore S, et al. P4-mediated antibody therapy in an acute model of invasive pneumococcal disease. J Infect Dis 2012; 205: 1399-1407.
206. Bangert M, Wright AK, Rylance J, et al. Immunoactivating peptide P4 augments alveolar macrophage phagocytosis in two diverse human populations. Antimicrob Agents Chemother 2013; 57: 4566-4569.